Lumito granted SEK 250,000 business development grant from Region Skåne
Lumito AB (publ) (“Lumito” or “the Company”) announces today that the Company has received a business development grant of SEK 250,000 from Region Skåne. Together with the proceeds from the recently completed rights issue, the funding will primarily be used to accelerate the Company’s commercial development and further strengthen its position in the European market.
“We are grateful that Region Skåne has chosen to support our continued commercialisation, international expansion, and development. This support reinforces our efforts and, together with the capital raised in the rights issue, enables us to increase the pace of key activities and strengthen our position in the market,” says Sanna Wallenborg, CEO of Lumito.
The funding will mainly provide Lumito with additional resources for its commercialisation initiatives. The support from Region Skåne strengthens the Company’s market position by enabling greater presence and visibility at strategically important congresses and trade fairs, as well as the development of sales support materials and application notes, which illustrate the broad range of use cases for Lumito’s product, Scizys. A small portion of the grant will be used for the continued development of the Company’s product offering.
For further information, please contact:
Sanna Wallenborg, CEO Lumito
E-mail: sw@lumito.se
Ph: +4670-870 01 68
About Lumito
Lumito specialises in medical technology and translational research in digital tissue imaging. Lumito offers a groundbreaking, highly sensitive imaging technique to locate and measure protein biomarkers in tissue samples using up-converting nanoparticles (UCNPs) through its patented research platform. The technology combines image data with precise biomarker detection, enabling images with higher contrast where irrelevant background information is filtered out. The technique can enhance the analysis of tissue samples by increasing objectivity, thereby contributing to research for more quantifiable diagnoses and optimised treatments. Lumito primarily focuses on drug development and digital pathology and is a spin-off from a research group at Lund University's Department of Atomic Physics and Laser Center. www.lumito.se/en/
The share is traded on NGM Nordic SME under the name LUMITO, and Mentor is Mangold Fondkommission.
Bifogade filer